Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...
Nvidia sold its entire 7.71 million share stake in Recursion Pharmaceuticals by December 31, 2025 Recursion stock swung 14% lower intraday Wednesday before closing 2% higher ARK Invest bought 1.25 ...
So, you want to get better at Java coding, huh? It’s a pretty popular language, and honestly, getting some hands-on practice is the best way to really learn it. Luckily, there are a bunch of places ...
Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...
Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Abstract: The vast availability of free data has been critical to the success of large language models (LLMs). With the widespread use of LLMs, more and more concerns have been raised about the ...
U.S. prosecutors last week levied criminal hacking charges against 19-year-old U.K. national Thalha Jubair for allegedly being a core member of Scattered Spider, a prolific cybercrime group blamed for ...
Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results